Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 10 mg - tablet, film coated - excipient ingredients: maltodextrin; magnesium stearate; macrogol 6000; hydrophobic colloidal silica anhydrous; lactose monohydrate; sodium starch glycollate; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: maltodextrin; hydrophobic colloidal silica anhydrous; lactose monohydrate; macrogol 6000; sodium starch glycollate; magnesium stearate; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; sodium starch glycollate; macrogol 6000; hydrophobic colloidal silica anhydrous; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - eplerenone - film-coated tablet - 25 milligram(s) - aldosterone antagonists; eplerenone

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - eplerenone - film-coated tablet - 50 milligram(s) - aldosterone antagonists; eplerenone

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; hyprolose; sodium starch glycollate type a; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hyprolose; magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; purified talc; microcrystalline cellulose; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.